Transcripts Novo Nordisk A/S

Actions

NOVO B

DK0062498333

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 13/05/2026			Varia. 5j.	Varia. 1 janv.
299,20 ^DKK	+0,91%		+3,07%	-8,01%

15/05	Les actions européennes négociées aux États-Unis sous forme d'ADR en forte baisse lors de la séance de vendredi	MT
15/05	Sandoz enrichit son offre d'insuline en Europe avec deux produits	AW

Transcripts

06/05	Transcript : Novo Nordisk A/S, Q1 2026 Earnings Call, May 06, 2026
26/03	Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
23/02	Transcript : Novo Nordisk A/S - Special Call
05/02	Transcript : Novo Nordisk A/S, Q4 2025 Earnings Call, Feb 05, 2026
04/02	Transcript : Novo Nordisk A/S, 2025 Earnings Call, Feb 04, 2026
13/01	Transcript : Novo Nordisk A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 09:45 AM
05/11	Transcript : Novo Nordisk A/S, Q3 2025 Earnings Call, Nov 05, 2025
21/10/25	Transcript : Novo Nordisk A/S - Special Call
17/09/25	Transcript : Novo Nordisk A/S - Special Call
08/08/25	Transcript : Novo Nordisk A/S, Q2 2025 Earnings Call, Aug 07, 2025
06/08/25	Transcript : Novo Nordisk A/S, Q2 2025 Earnings Call, Aug 06, 2025
29/07/25	Transcript : Novo Nordisk A/S - Special Call
25/06/25	Transcript : Novo Nordisk A/S - Special Call
23/06/25	Transcript : Novo Nordisk A/S - Special Call
16/05/25	Transcript : Novo Nordisk A/S - Special Call
07/05/25	Transcript : Novo Nordisk A/S, Q1 2025 Earnings Call, May 07, 2025
27/03/25	Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
05/02/25	Transcript : Novo Nordisk A/S, 2024 Earnings Call, Feb 05, 2025
07/11/24	Transcript : Novo Nordisk A/S - Special Call
06/11/24	Transcript : Novo Nordisk A/S, Q3 2024 Earnings Call, Nov 06, 2024
08/08/24	Transcript : Novo Nordisk A/S - Special Call
07/08/24	Transcript : Novo Nordisk A/S, H1 2024 Earnings Call, Aug 07, 2024
03/05/24	Transcript : Novo Nordisk A/S - Special Call
02/05/24	Transcript : Novo Nordisk A/S, Q1 2024 Earnings Call, May 02, 2024
21/03/24	Transcript : Novo Nordisk A/S - Shareholder/Analyst Call